| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Division of Pathology and Laboratory Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
Follicular lymphoma is characterized by the presence of the t(14;18)(q32;q21) chromosomal translocation which juxtaposes the bcl-2 gene at 18q21 with the immunoglobulin heavy chain locus at 14q32. Quantification of t(14;18) carrying cells in FL patients can be achieved by real-time PCR, a highly sensitive technique for evaluating treatment efficacy and minimal residual disease. Despite the many advantages of real-time technology for this purpose, one disadvantage is that current real-time t(14;18) PCR assays amplify a control gene as a normalizer in a separate reaction. Since each PCR reaction has its own kinetics, separate PCR assays for target and control sequences can potentially result in inaccurate quantification of t(14;18)-positive cells. In addition, the real-time t(14;18) PCR assays do not determine the size of the amplified fusion sequence, which is helpful for excluding contamination and is commonly used to demonstrate clonal identity between pre- and post-treatment specimens from a patient. To address these limitations, we designed a multiplex real-time PCR protocol that allows amplification of control and target genes in the same reaction and precise size determination of bcl-2/JH fusion sequences by capillary electrophoresis. This multiplex PCR assay is equally sensitive to previous assays, allows more accurate quantification of bcl-2/JH fusion sequences, and is more convenient.
This article has been cited by other articles:
![]() |
S. A. Jacobs, S. H. Swerdlow, J. Kant, K. A. Foon, R. Jankowitz, S. R. Land, N. DeMonaco, J. Joyce, J. L. Osborn, T. L. Evans, et al. Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma Clin. Cancer Res., November 1, 2008; 14(21): 7088 - 7094. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. F. Khouri, P. McLaughlin, R. M. Saliba, C. Hosing, M. Korbling, M. S. Lee, L. J. Medeiros, L. Fayad, F. Samaniego, A. Alousi, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab Blood, June 15, 2008; 111(12): 5530 - 5536. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Pennell, A. Woods, M. Reis, R. Buckstein, D. Spaner, K. Imrie, K. Hewitt, A. Boudreau, A. Seth, and N. L. Berinstein Association of Clinical Status of Follicular Lymphoma Patients after Autologous Stem Cell Transplant and Quantitative Assessment of Lymphoma in Blood and Bone Marrow as Measured by SYBR Green I Polymerase Chain Reaction J. Mol. Diagn., February 1, 2006; 8(1): 40 - 50. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Luthra and L. J. Medeiros Isothermal Multiple Displacement Amplification: A Highly Reliable Approach for Generating Unlimited High Molecular Weight Genomic DNA from Clinical Specimens J. Mol. Diagn., August 1, 2004; 6(3): 236 - 242. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |